Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.

Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity.

Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

Abstract: The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.

Abstract: Antibodies and antigen binding fragments that bind specifically to TNFRSF25 are provided herein. Methods for using the antibodies and antigen binding fragments to, for example, stimulate proliferation of human T cells (e.g., CD8+ T cells) and to treat cancer patients also are provided.

Abstract: The present invention relates to methods of treating liver cancer using a Notch signaling inhibitor. Compositions and methods for the treatment of liver cancers are also provided.

Abstract: The present invention relates to a pharmaceutical composition for treatment and/or prevention of cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 or more consecutive amino acids.

Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.

Abstract: A transgenic non-human animal is provided. In certain embodiments, the animal comprises a genome comprising an immunoglobulin heavy chain locus comprising: a) a transcribed gene encoding a fusion protein comprising, from N-terminus to C-terminus: i. a scaffold comprising a first binding domain; and ii. a heavy chain constant region operably linked to the scaffold; wherein the scaffold is capable of specifically binding to a target in the absence of additional polypeptides; and b) a plurality of pseudogenes that are operably linked to the transcribed gene and that donate, by gene conversion, nucleotide sequence to the part of the transcribed gene that encodes the binding domain.

Abstract: The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.

Abstract: The present invention provides a process for preparing an inhibited starch comprising, in order: a) extracting starch from a native source and partially refining to provide a partially refined starch having a residual protein content on a dry starch basis of more than 0.4% by weight and less than 8.0% by weight; b) treating said partially refined starch with a bleaching agent to provide an inhibited starch; and c) recovering said inhibited starch.

Abstract: Production of a conjugated diene rubber includes polymerizing isoprene or a monomer mixture containing isoprene and an aromatic vinyl monomer in an inert solvent by using a polymerization initiator so as to form a polymer block (A) having an active end, mixing the polymer block (A) having an active end and 1,3-butadiene or a monomer mixture containing 1,3-butadiene and an aromatic vinyl monomer to continue a polymerization reaction so as to obtain a conjugated diene polymer chain having an active end and containing a polymer block (A) and a polymer block (B), and reacting a compound represented by the following general formula (1) with the active end of the conjugated diene polymer chain having an active end:

Abstract: A method for purifying a reclaimed polymer, such as a polymer reclaimed from post-consumer use or post-industrial use, is disclosed. The method involves obtaining the reclaimed polymer and contacting it at an elevated temperature and pressure with a fluid solvent to produce an extracted reclaimed polymer. The extracted reclaimed polymer is dissolved in a solvent at an elevated temperature and pressure to produce a polymer solution, which is purified at an elevated temperature and pressure by contacting the polymer solution with solid media to produce a purer polymer solution. A purer polymer is then separated from the purer polymer solution.

Abstract: This invention relates to a process to polymerize olefins comprising: i) contacting one or more olefins with a catalyst system comprising: 1) a support comprising an organoaluminum treated layered silicate and an inorganic oxide; and 2) a pyridyldiamido compound; and ii) obtaining olefin polymer having high molecular weight and layered silicate dispersed therein. Preferably the support is in the form of spheroidal particles.

Abstract: The invention provides a redox flow battery comprising a microporous or nanoporous size-exclusion membrane, wherein one cell of the battery contains a redox-active polymer dissolved in the non-aqueous solvent or a redox-active colloidal particle dispersed in the non-aqueous solvent. The redox flow battery provides enhanced ionic conductivity across the electrolyte separator and reduced redox-active species crossover, thereby improving the performance and enabling widespread utilization. Redox active poly(vinylbenzyl ethylviologen) (RAPs) and redox active colloidal particles (RACs) were prepared and were found to be highly effective redox species. Controlled potential bulk electrolysis indicates that 94-99% of the nominal charge on different RAPs is accessible and the electrolysis products are stable upon cycling. The high concentration attainable (>2.

Abstract: The following are provided: a water-absorbent resin in which, in the formation of an absorbent material forming an absorbent article, dispersion is satisfactory even in a moisture absorption state, which prevents the occurrence of troubles at the time of manufacturing of the absorbent article and which allows efficient manufacturing; and an absorbent article using an absorbent material containing the water-absorbent resin. The water-absorbent resin according to the present invention is obtained by polymerizing a water-soluble ethylenically unsaturated monomer and performing post-crosslinking thereon with a post-crosslinking agent, and the water-absorbent resin satisfies the requirements below: (A) yellow index is 5.0 or less; and (B) gel strength is 1800 Pa or less.

Abstract: A process for polymerizing radically (co)polymerizable monomers at a temperature between ?10° C. and 110° C. in an aqueous system comprising one or more radically (co)polymerizable monomer(s) is disclosed, and includes a molar excess of a ligand forming a soluble transition metal complex with an added transition metal salt that participates in a reversible reduction-oxidation cycle with one of an added site specific functional initiator and a dormant polymer chain having a radically transferable atom or group. The initial soluble catalyst complex concentration in the higher oxidation state is less than or equal to 2500 ppm. The reaction is conducted in the presence of an activator regenerator. The mole fraction of the soluble lower activator oxidation state transition metal formed by action of the activator regenerator, to transition metal in a higher deactivator oxidation state is less than 10%. The formed polymer chains have a dispersity of less than 1.5.

Abstract: There are provided a novel cyclic olefin compound having a photoreactive group and a photoreactive polymer. The cyclic olefin compound is applicable to various photoreactions, such as of liquid crystal alignment layers and can be preferably used as a precursor of various organic compounds or polymers.

Abstract: A process for the preparation of optionally asymmetric acetal compounds includes reacting a compound containing a hydroxyl group with a vinylether compound in the presence of a zwitterionic catalyst including at least one basic nitrogen containing structural fragment and at least one sulfonic acid group in its structure, with the proviso that a molar ratio of the basic nitrogen to sulfonic acid is 1:1.

Abstract: The present disclosure relates to the homopolymerization of terpenoids containing an alcohol functional group by free radical polymerization.

Abstract: Disclosed is a method of making packaging material for polymers susceptible to oxidation. The packaging material utilizes a composite foil. The composite foil has at least three layers and have barrier layers based on polyvinyl alcohols. The composite foil may be used to package polymers susceptible to oxidation. Also disclosed is a process for packaging the polymers and the packaging composed of the composite foil.

Abstract: A polyisoolefin-based polymer composition having a multimodal molecular weight distribution and a level of unsaturation of greater than about 4 mol % is described, which can be prepared by co-polymerizing 70-96 vol % isoolefin monomer and 30-4 vol % ?-pinene or multi-olefin monomer, based on volume of isoolefin monomer and ?-pinene or multi-olefin monomer, in a solution comprising 0-30 vol % aliphatic hydrocarbon diluent, based on volume of the solution, and an alkylaluminum halide initiator system. The polyisoolefin-based polymer composition has a multimodal molecular weight distribution having a first molecular weight fraction having a peak molecular weight (Mp) of less than about 300 kg/mol, and a second molecular weight fraction having a peak molecular weight (Mp) of greater than about 1000 kg/mol or at least 3 times greater than the Mp of the first molecular weight fraction.

Abstract: A catalyst system including the reaction product of a fluorided support, an activator, and at least a first transition metal catalyst compound; methods of making such catalyst systems, polymerization processes using such catalyst systems, and polymers made therefrom.

Abstract: The present disclosure provides high density polyethylene resins having good low temperature impact resistance. The resins are suitable for use in rotomolding application for large parts. The resin is a bi- or trimodal resin produced using solution phase polymerization in the presence of a single site catalyst.

Abstract: A copolymer, a method for producing the copolymer, a porous structure formed by the copolymer, a method for producing the porous structure, and a porous carbon sphere formed by carbonizing the porous structure are shown. The copolymer has a chemical structure of formula (1) or (2): wherein the molecular weight of the copolymer structure is 120,000 or less g/mole, m and t are both greater than 0, 8%?p?80%, y?0, z?0, and X is selected from —Cl, —Br and —I.

Abstract: Described herein is polymer melt additive composition for use as a processing aid in the extrusion of a non-fluorinated polymer, the polymer melt additive composition comprising a fluorine-containing polymer derived from the polymerization of a monomer and a sulfinate-containing molecule, wherein the sulfinate-containing molecule is selected from the group consisting of: (a) CX1X3?CX2—(R)p—CZ1Z2—SO2M??Formula (I) (b) ?and (c) combinations thereof, wherein X1, X2, and X3 are each independently selected from H, F, Cl, a C1 to C4 alkyl group, and a C1 to C4 fluorinated alkyl group; R is a linking group; Z1 and Z2 are independently selected from F, CF3, and a perfluoroalkyl group; R1 and R2 are end-groups; p is 0 or 1; m is at least 2; and M is a cation.

Abstract: A photocurable composition contains at least one ultraviolet absorber represented by Formula (1), and a hard coating agent including the photocurable composition. wherein R1, R2 and R3 may be the same as or different from each other and represent a branched or linear alkyl group with 1-20 carbon atoms and is substituted with a (meth)acryloyloxy group; the alkyl group may be substituted with a hydroxyl group, an alkoxy group having 1-8 carbon atoms, or an acyloxy group having 1-8 carbon atoms; the alkyl group may be interrupted by an oxygen atom, a sulfur atom, a carbonyl group, an ester group, an amide group, or an imide group; and R4, R5 and R6 may be the same as or different from each other and represent a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group having 1-12 carbon atoms, or an alkoxy group having 1-12 carbon atoms.

Abstract: A process for making a branched cyclic olefin copolymer (bCOC), and the bCOC therefrom, comprising combining at a temperature within a range from 60° C. to 140° C. a catalyst precursor and an activator with a feed comprising ethylene and at least one cyclic olefin; where the catalyst precursor is selected from the group consisting of CS-symmetric Group 4 metallocenes comprising any two ligands selected from cyclopentadienyl and ligands isolobal to the cyclopentadienyl group. The resulting bCOC is desirably semi-crystalline and useful in such articles as tubing, thermoformed and foamed articles.

Abstract: Embodiments of the present technology include a formaldehyde-free binder composition. The composition may include melamine. The composition may also include a reducing sugar. In addition, the binder composition may include a non-carbohydrate aldehyde or ketone. Embodiments may also include a method of making a formaldehyde-free binder composition. The method may include dissolving melamine in an aqueous solution of a reducing sugar. The concentration of the reducing sugar may be 30 wt. % to 70 wt. % of the aqueous solution, which may be at a temperature of 50° C. to 100° C. The method may also include adding a non-carbohydrate aldehyde or ketone to the dissolved melamine in the aqueous solution to form a binder solution. The temperature of the aqueous solution of the dissolved melamine may be 50° C. to 100° C. during the addition of the non-carbohydrate aldehyde or ketone. The method may further include reducing the temperature of the binder solution.

Abstract: A composition for forming a polyiso-urea includes a capped polycarbodiimide and a polyol. The capped polycarbodiimide comprises the reaction product of a diisocyanate and a monoisocyanate in the presence of an oxygen scavenger and a carbodiimidization catalyst and in the absence of solvent, has 0.25 wt. % or less of free isocyanate groups, and is a liquid at 25° C. A polyiso-urea comprises the reaction product of the capped polycarbodiimide and the polyol.

Abstract: A composition including a compound containing a carbon-carbon double bond obtained by reacting (A) a polyisocyanate which is a trimer of diisocyanate, with (B) a compound having an active hydrogen, wherein component (B) includes: (B1) a perfluoropolyether having an active hydrogen, (B2) a silane compound having an active hydrogen, and (B3) a monomer having an active hydrogen and a carbon-carbon double bond. Further, a molar amount of an isocyanate group in component (A) is equal to a total molar amount of component (B), and a molar amount of component (B1), component (B2) and component (B3) per 9 moles of the isocyanate group in component (A) are component (B1) 0.1-2 moles, component (B2) 0.05-2 moles, and component (B3) 5-8.85 moles, respectively.

Abstract: Described are a method of producing polyurethane foam comprising polyolefin-based polyols by using an additive composition comprising at least one ionic surfactant A selected from ionic surfactants of formula A?M+, where A?=anion selected from the group consisting of alkyl sulphates, aryl sulphates, sulphonates, polyether sulphates, polyether sulphonates, alkyl sulphonates, aryl sulphonates, alkyl carboxylates, aryl carboxylates, saccharinates and polyether phosphates, and M+=cation, and/or at least one ionic surfactant B selected from a quaternized ammonium compound, and also at least a tertiary amine compound C having a molar mass of at least 150 g/mol, and/or an oxazasilinane D, and also polyurethane foams thus obtained and their use.

Abstract: An embodiment relates to a resin composition containing a tetraglycidyl amine; a bisphenol epoxy; a dicyandiamide; and an aromatic urea; wherein the tetraglycidyl amine has a EEW of 110 g/eq to 140 g/eq and is an amount of 30 to 60 PHR per 100 PHR of total epoxy resin in the resin composition; wherein the resin composition has a Tg of at least 160° C. when cured at 143° C. for 3 min and also maintains a Tg of greater than 160° C. when cured at 177 C for 1 min or longer.

Abstract: A method is provided for producing a compound, including a step of mixing a compound (1) having one or two leaving groups, a compound (2) having one or two boron atom-containing leaving groups, an organic base (P), and at least one selected from a phase transfer catalyst and an organic base (Q) larger in the number of carbon atoms than the above-mentioned organic base in the presence of a transition metal catalyst. The method thereby performs a coupling reaction between the above-mentioned compound (1) and the above-mentioned compound (2).

Abstract: The present disclosure describes a polyester that contains plural pendant adjacent carboxylic acid or acid salt side groups for use in making a toner for use in imaging devices.

Abstract: The subject of the invention is a method to manufacture polyester resins using a by-product formed during a process of oxidizing cyclohexane to cyclohexanol and cyclohexanone, which contains a mixture of carboxyl acids; the method comprises a heating process with the removal of water and low-boiling residues as well as a polycondensation process with di- and polyhydroxy alcohols under a reduced pressure; the method described is characterized by that a water layer is applied as a baseline material in the synthesis; the said water layer is separated from the residues left over after the hydrolysis of cyclohexyl esters contained in the cyclohexane oxidation product, and after the main components, cyclohexanol and cyclohexanon, have been first separated from the said product: thereafter, the water layer is condensed.

Abstract: The present invention relates to a method for manufacturing polydioxanone particles (PDO) for a filler, more particularly to a method for manufacturing polydioxanone particles, which includes a step of mixing a solution of polydioxanone dissolved in a perfluoroalcohol with a polymer emulsion containing a polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer at a predetermined ratio to generate polydioxanone particles and then recovering the polydioxanone particles through aging and washing. The polydioxanone particles manufactured by the manufacturing method of the present invention can be favorably used as an injection for regenerating skin tissues.

Abstract: Described herein is a peroxide curable, highly fluorinated elastomer derived from (a) a fluorinated di-iodo ether compound of the following formula I: Rf—CF(I)—(CX2)n—(CX2CXR)m—O—R?f-Ok—(CXR?CX2)p—(CX2)q—CF(I)—R?f wherein X is independently selected from F, H, and Cl; Rf and R?f are independently selected from F and a monovalent perfluoroalkane having 1-3 carbons; R is F, or a partially fluorinated or perfluorinated alkane comprising 1-3 carbons; R?f is a divalent fluoroalkylene having 1-5 carbons or a divalent fluorinated alkylene ether having 1-8 carbons and at least one ether linkage; k is 0 or 1; and n, m, and p are independently selected from an integer from 0-5, with the proviso that when k is 0, n+m is at least 1 and p+q is at least 1; and (b) a fluorinated monomer.

Abstract: The efficient production of poly(tetramethylene ether) diacetate [PTMEA] or other diesters, from tetrahydrofuran [THF] is obtained utilizing an acid-based catalyst that is based on a morphologically reconfigured and Bronsted acidity enhanced halloysite derived from a preparation method of using naturally occurring halloysites. More specifically, the method relates to morphological modification of the internal pore structure of halloysites via supercritical carbon dioxide treatment directly applied onto the raw halloysite minerals, that yields highly synergistic and reproducible results of elimination of inaccessible and detrimental extra-small pores. PTMEA is readily converted to poly(tetramethylene ether) glycol (PTMEG) by a transesterification reaction.

Abstract: Nylon 7 may be produced from biomass derived 6-carbon hydroxymethyl furan compounds as the raw material. The hydroxymethyl furan compounds may be homologated to form an aldehyde that may be aminated to produce an amino carbonyl compound. Hydrogenation/hydro-deoxygenation of the amino-carbonyl compound provides nylon 7.

Abstract: Methods and compounds for producing nylon 6 are disclosed. Di-substituted furanic compounds may be used as the raw material for producing precursor compounds for nylon 6, and the precursor compounds are convertible to nylon 6.

Abstract: The invention relates to new compounds of Formula 1: wherein R, R1, are each independently hydrogen, a linear or branched C1-40 alkyl, C2-40-alkenyl or C2-40-alkynyl group, an aryl or C1-40-alkylaryl group; X is H, OH, O(Mn)1/n or R4 where M is a metal ion derived from a lanthanide, actinide, main group or transition metal and V is a substituted C1-40-alkyl, C2-40-alkenyl or C2-40-alkynyl group or an aryl group or C1-40-alkylaryl sulfide, sulfoxide, sulfone, amine or a polyalkyl amine or phosphine or other phosphorous containing group; R4 is a linear or branched C1-40 alkyl, C2-40-alkenyl or C2-40-alkynyl group, an aryl or C1-40-alkylaryl group; e is an integer from 0 to 2; f is an integer from 1 to 100; n is an integer from 1 to 4: the free valences of the silicate oxygen atoms are saturated by one or more of: silicon atoms of other groups of Formula 1, hydrogen, a linear or branched C1-12-alkyl group or by cross-linking bridge members or by polymer chains (R2)2Si(OR3)1O1/2 or (R2)2SiO2/2 or (R2)3SiO1/2

Abstract: A composition comprises at least one condensed phosphorus compound. The condensed phosphorus compound is produced by reacting together in a condensation reaction a nitrogen compound and a phosphonium compound. A phosphorus-containing polymer is produced by reacting in a condensation reaction a hydroxyalkylphosphonium compound to produce an intermediate polymer and then oxidizing phosphorus atoms in the intermediate polymer to yield a polymer comprising phosphine oxide groups.

Abstract: A high-chi diblock copolymer (BCP) for self-assembly comprises a first block comprising repeat units of trimethylsilyl styrene (TMSS) and styrene, and a second block comprising an aliphatic carbonate repeat unit. The blocks are linked together by a fluorinated junction group L? in which none of the fluorines of L? are covalently bound to an atomic center of the polymer backbone. A top-coat free film layer comprising the BCP, which is disposed on an underlayer and in contact with an atmosphere, is capable of forming a perpendicularly oriented lamellar domain pattern on an underlayer that is preferential or non-preferential to the domains of the block copolymer. The domain pattern can be selectively etched to provide a relief pattern comprising a remaining domain. The relief pattern having good critical dimensional uniformity compared to an otherwise identical polymer lacking the silicon.

Abstract: Adding a compatible high melt flow rate (MFR), low melt viscosity, hydrogenated styrene block copolymer to amorphous poly alpha-olefins (APAOs) results in adhesives that show acceptably high elongation and tensile strength, and which, when applied by different hot melt application methods onto elastic strands, result in personal hygiene article components that perform comparably to such components assembled using just styrene block copolymer components formulated with compatible tackifiers, processing oils and other additives.

Abstract: A method of modifying polyolefin to have long chain branching comprising mixing polyolefin and a photoinitiator and irradiating the mixture with UV radiation. The modified polyolefin of the method and the use of said modified polyolefin.